| Efficacy and safety of combination chemotherapy with docetaxel and cisplatin as a first-line treatment for advanced gastric cancer |
|
Gyung Jung Kim, Sehe Dong Lee, Jong Won Park, Cheol Ho Sin, Seung Jae Hwang, Seung Hyun Nam, Bong Seog Kim |
|
고려대학교 의과대학 내과학교실 |
| 원저 : 진행성 위암에 대한 1차 요법으로 Docetaxel과 Cisplatin 복합화학요법의 효과와 안정성에 대한 연구 |
|
김경중, Sehe Dong Lee, Jong Won Park, Cheol Ho Sin, Seung Jae Hwang, Seung Hyun Nam, Bong Seog Kim |
|
|
|
|
|
|
| Abstract |
Background : To evaluate the activity and safety of docetaxel and cisplatin for advanced gastric cancer as a first-line chemotherapy treatment.
Methods
: Between December 2001 and February 2006, forty-two patients with recurrent or metastatic gastric cancer were enrolled. Docetaxel (75 mg/m2) was administered as a 1-hour intravenous infusion on day 1 and cisplatin (60 mg/m2) was also administered as a 30-minute intravenous infusion on day 1 every three weeks until disease progression or severe toxicity was detected. The response was assessed every 2 cycles. The toxicities were evaluated for every course of chemotherapy according to NCI toxicity criteria.
Results
: The median age of the patients was 66 (range, 33～77) years. Among the forty-two patients, 38 were male.
Twenty-seven patients had an Eastern Cooperative Oncology Group performance score of 0 or 1 and fifteen patients had a score of 2. All patients had adenocarcinoma. Thirty-three of the forty-two patients were assessable for response.
Partial responses were observed in 14 patients. The overall response rate was 42.4% (95% C.I., 25.259.6%) and the median response duration was 5.7 (range, 1.4～17.2) months. The median overall survival of all patients was 8.1 (range, 1.2～47.0) months. During a total of 170 cycles, granulocytopenia worse than National Cancer Institute toxicity grade 3 occurred in 7.6% of the patients, thrombocytopenia in 0.6% and anemia in 3.5%, respectively. No deaths resulting from toxicity were observed. Non-hematologic toxicities were minor and were easily controlled.
Conclusion
: Combination chemotherapy with docetaxel and cisplatin has a tolerable efficacy with acceptable toxicities in patients with advanced gastric cancer as a first-line treatment.(Korean J Med 72:593-599, 2007)
Key Words : Advanced castric cancer, Docetaxel, Cisplatin |
| Key Words:
Advanced castric cancer, Docetaxel, Cisplatin |
|
PDF Links
Full text via DOI
Download Citation
